Hagimoto Jin, Chief Financial Officer Takashi Miyoshi, IR General Manager PLAY LIST from the beginning Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024) Forward-Looking Statements and Use of Document Highlights P&L, FCF OP Variance Analysis (Q3): Higher sales driven by continued demand OP Variance Analysis (Q3 YTD): Contribution from pricing measures and strong sales Revenue by Region: Steady progress globally, driven by US and Europe C&V: Global sales and profit exceeded planned figures, driven by US TMCS: Revenues and profits increased due to strong sales including one-time factors and the effects of pricing measures TBCT: Both sales and income increased due to accelerated development of the plasma innovation business Reference P&L (QoQ) SG&A (QoQ) SG&A (YoY) Adjusted Operating Profit: Adjustments CAPEX, Depreciation and Amortization, R&D Expenses Cash Flow (Q3 YTD) Cash Flow (Q3) Free Cash Flow:93.9 B JPY(YoY +55.8 B JPY) Foreign Exchange Sensitivity @ Back Next